Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/a6219535-ea2f-4fc5-861f-203d4a62ab55/

JAZZ

Jazz Pharmaceuticals PLC
Chart
$238.57
Latest Week 2026-06-05
HealthcareBiotechnologyLARGE
Snapshot 2026-06-07 · 0.0w · Fresh
0.53
OS Score
14.0%
Value
77.0%
Quality
93.0%
Momentum
5/9
F-Score
0.328
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
2 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
12-1 103%
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
RAM 2.81
V
Value Analysis
Cheapness relative to fundamentals
14.0%ile
P/E
534.7×
P/S
3.6×
P/B
3.5×
E/P
0.0019
FCF Yield
0.075
EBITDA/EV
0.020
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
93.00000000
/100 — 1=cheapest
VC2 (Trending Value)
93.00000000
/100
VC3 (Buyback)
93.00000000
/100
P/E of 534.7x is premium-priced — the market is paying up for expected growth. FCF yield of 7.5% is strong — the business generates significant free cash relative to price. VC2 score of 93.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
77.0%ile
ROE
0.007
ROA
0.002
Net Margin
0.007
Op Margin
-0.037
GPA
0.315
D/E
1.62
Current
2.04
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.092
Earn Growth
-0.939
Stability
5.265
lower=better
Accruals
-0.110
lower=better
5yr Consist
No
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
93.0%ile
6M Return
40.6%
12M Return
114.7%
12-1 Mom
103.2%
Risk-Adj
2.81
Vol 252d
36.7%
Vol 60d
89.7%
↑ Expanding
Max DD 12M
-8.9%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 103% is very strong — a clear uptrend. Risk-adjusted momentum of 2.81 is excellent — strong returns relative to volatility. Near-term vol (90%) is expanding vs long-term (37%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.53
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
5.0%
Sector Quality %ile
84.6%
P/E z-score
17.16
P/B z-score
-0.13
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Quality Momentum — Expensive
Strong quality (77th) and momentum (93th) but expensive (14th value). Premium priced — watch for mean reversion.
Quality at a Premium
High quality (77th) but expensive (14th value). Upside may be limited without earnings growth.
Volatility Expanding
60-day vol (90%) significantly exceeds 252-day (37%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
D
32.6% avg (7 factors)
Quality
D
38.8% avg (8 factors)
Momentum
A
95.8% avg (4 factors)
Risk
C
55.4% avg (1 factors)
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.530—0—
Value %ile0.140—1—
Quality %ile0.770—1—
Momentum %ile0.930—1—
F-Score5.000—0—
Confidence0.970—1—
Volatility0.367—0—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
534.69
Earnings Yield (E/P)
0.0019
Price / Sales
3.55
Price / Book
3.48
Price / Cash Flow
11.82
FCF Yield
7.5%
EBITDA / EV
2.0%
Sales Yield (1/P·S)
0.2300
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
0.7%
Return on Assets
0.2%
Net Margin
0.7%
Operating Margin
-3.7%
Gross Profit / Assets
Novy-Marx GPA
31.5%
Debt / Equity
1.62
Current Ratio
2.04
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.110
MomentumPrice trend strength over different horizons
6M Return
40.6%
12M Return
114.7%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
103.2%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
2.81
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
9.2%
Earnings Growth (YoY)
-93.9%
Earnings Stability (CV)
Lower = more stable
5.265
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
5
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
93
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
93
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
93
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity